Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 142

1.

Relationship between In Vivo CYP3A4 Activity, CYP3A5 Genotype, and Systemic Tacrolimus Metabolite/Parent Drug Ratio in Renal Transplant Recipients and Healthy Volunteers.

Vanhove T, de Jonge H, de Loor H, Oorts M, de Hoon J, Pohanka A, Annaert P, Kuypers DRJ.

Drug Metab Dispos. 2018 Nov;46(11):1507-1513. doi: 10.1124/dmd.118.081935. Epub 2018 Aug 30.

PMID:
30166405
2.

In vivo CYP3A4 activity does not predict the magnitude of interaction between itraconazole and tacrolimus from an extended release formulation.

Vanhove T, Annaert P, Knops N, de Loor H, de Hoon J, Kuypers DRJ.

Basic Clin Pharmacol Toxicol. 2019 Jan;124(1):50-55. doi: 10.1111/bcpt.13092. Epub 2018 Aug 14.

PMID:
29989304
3.

"What do we know about tacrolimus pharmacogenetics in transplant recipients?"

Kuypers DR.

Pharmacogenomics. 2018 May;19(7):593-597. doi: 10.2217/pgs-2018-0035. Epub 2018 Apr 27. No abstract available.

PMID:
29701126
4.

Kuypers and Vanhove reply to 'Was 4β-hydroxycholesterol ever going to be a useful marker of CYP3A4 activity?' by Neuhoff and Tucker.

Kuypers DRJ, Vanhove T.

Br J Clin Pharmacol. 2018 Jul;84(7):1622-1623. doi: 10.1111/bcp.13592. Epub 2018 Apr 24. No abstract available.

PMID:
29691891
5.

Tacrolimus Formulations and African American Kidney Transplant Recipients: When Do Details Matter?

Kuypers DRJ.

Am J Kidney Dis. 2018 Mar;71(3):302-305. doi: 10.1053/j.ajkd.2017.10.020. No abstract available.

PMID:
29477174
6.

Prospective randomized study of conversion from tacrolimus to cyclosporine A to improve glucose metabolism in patients with posttransplant diabetes mellitus after renal transplantation.

Wissing KM, Abramowicz D, Weekers L, Budde K, Rath T, Witzke O, Broeders N, Kianda M, Kuypers DRJ.

Am J Transplant. 2018 Jul;18(7):1726-1734. doi: 10.1111/ajt.14665. Epub 2018 Feb 22.

PMID:
29337426
7.

Pretransplant 4β-hydroxycholesterol does not predict tacrolimus exposure or dose requirements during the first days after kidney transplantation.

Vanhove T, Hasan M, Annaert P, Oswald S, Kuypers DRJ.

Br J Clin Pharmacol. 2017 Nov;83(11):2406-2415. doi: 10.1111/bcp.13343. Epub 2017 Jul 14.

8.

Tubulointerstitial expression and urinary excretion of connective tissue growth factor 3 months after renal transplantation predict interstitial fibrosis and tubular atrophy at 5 years in a retrospective cohort analysis.

Vanhove T, Kinashi H, Nguyen TQ, Metalidis C, Poesen K, Naesens M, Lerut E, Goldschmeding R, Kuypers DRJ.

Transpl Int. 2017 Jul;30(7):695-705. doi: 10.1111/tri.12960. Epub 2017 May 9.

9.

Practical Recommendations for Long-term Management of Modifiable Risks in Kidney and Liver Transplant Recipients: A Guidance Report and Clinical Checklist by the Consensus on Managing Modifiable Risk in Transplantation (COMMIT) Group.

Neuberger JM, Bechstein WO, Kuypers DR, Burra P, Citterio F, De Geest S, Duvoux C, Jardine AG, Kamar N, Krämer BK, Metselaar HJ, Nevens F, Pirenne J, Rodríguez-Perálvarez ML, Samuel D, Schneeberger S, Serón D, Trunečka P, Tisone G, van Gelder T.

Transplantation. 2017 Apr;101(4S Suppl 2):S1-S56. doi: 10.1097/TP.0000000000001651.

PMID:
28328734
10.

Determinants of the Magnitude of Interaction Between Tacrolimus and Voriconazole/Posaconazole in Solid Organ Recipients.

Vanhove T, Bouwsma H, Hilbrands L, Swen JJ, Spriet I, Annaert P, Vanaudenaerde B, Verleden G, Vos R, Kuypers DRJ.

Am J Transplant. 2017 Sep;17(9):2372-2380. doi: 10.1111/ajt.14232. Epub 2017 Apr 8.

11.

Clinical Trials for Immunosuppression in Transplantation: The Case for Reform and Change in Direction.

OʼConnell PJ, Kuypers DR, Mannon RB, Abecassis M, Chadban SJ, Gill JS, Murphy B, Nickerson PW, Schold JD, Stock PG, Seron D, Alloway RR, Bromberg JS, Budde K, Jordan SC, Legendre C, Lefaucheur C, Sarwall M, Segev DL, Stegall MD, Tullius SG, Wong G, Woodle ES, Ascher N, Morris RE.

Transplantation. 2017 Jul;101(7):1527-1534. doi: 10.1097/TP.0000000000001648.

PMID:
28207630
12.

Response to: 'Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance'.

Vanhove T, Annaert P, Kuypers DRJ.

Br J Clin Pharmacol. 2017 Jun;83(6):1353-1356. doi: 10.1111/bcp.13249. Epub 2017 Feb 20. No abstract available.

13.

Predictive Modeling of Tacrolimus Dose Requirements: "All That Is Gold Does Not Glitter".

Kuypers DR, Vanhove T.

Am J Transplant. 2017 Apr;17(4):1144-1145. doi: 10.1111/ajt.14108. Epub 2016 Dec 9. No abstract available.

14.

Incidence of Posttransplantation Diabetes Mellitus in De Novo Kidney Transplant Recipients Receiving Prolonged-Release Tacrolimus-Based Immunosuppression With 2 Different Corticosteroid Minimization Strategies: ADVANCE, A Randomized Controlled Trial.

Mourad G, Glyda M, Albano L, Viklický O, Merville P, Tydén G, Mourad M, Lõhmus A, Witzke O, Christiaans MHL, Brown MW, Undre N, Kazeem G, Kuypers DRJ; Advagraf-based immunosuppression regimen examining new onset diabetes mellitus in kidney transplant recipients (ADVANCE) study investigators.

Transplantation. 2017 Aug;101(8):1924-1934. doi: 10.1097/TP.0000000000001453.

15.

Comparative performance of oral midazolam clearance and plasma 4β-hydroxycholesterol to explain interindividual variability in tacrolimus clearance.

Vanhove T, de Jonge H, de Loor H, Annaert P, Diczfalusy U, Kuypers DR.

Br J Clin Pharmacol. 2016 Dec;82(6):1539-1549. doi: 10.1111/bcp.13083. Epub 2016 Sep 20.

16.

Updated Manufacturer and European Medicines Agency Recommendations on the Use of Mycophenolate Acid: Balancing the Risks for Male Allograft Recipients.

Kuypers DR, Van Mieghem T, Meijers B, Claes K.

Transplantation. 2016 Sep;100(9):e50-1. doi: 10.1097/TP.0000000000001342. No abstract available.

PMID:
27472093
17.

Effect of ABCB1 diplotype on tacrolimus disposition in renal recipients depends on CYP3A5 and CYP3A4 genotype.

Vanhove T, Annaert P, Lambrechts D, Kuypers DRJ.

Pharmacogenomics J. 2017 Dec;17(6):556-562. doi: 10.1038/tpj.2016.49. Epub 2016 Jul 5.

PMID:
27378609
18.

High Intrapatient Variability of Tacrolimus Concentrations Predicts Accelerated Progression of Chronic Histologic Lesions in Renal Recipients.

Vanhove T, Vermeulen T, Annaert P, Lerut E, Kuypers DRJ.

Am J Transplant. 2016 Oct;16(10):2954-2963. doi: 10.1111/ajt.13803. Epub 2016 Apr 21.

19.

Clinical determinants of calcineurin inhibitor disposition: a mechanistic review.

Vanhove T, Annaert P, Kuypers DR.

Drug Metab Rev. 2016;48(1):88-112. doi: 10.3109/03602532.2016.1151037. Epub 2016 Feb 25. Review.

PMID:
26912097
20.

Response to 'Tacrolimus pharmacokinetics after kidney transplantation--Influence of changes in haematocrit and steroid dose'.

Vanhove T, de Jonge H, de Loor H, Verbeke K, Kuypers DR.

Br J Clin Pharmacol. 2015 Dec;80(6):1473-4. doi: 10.1111/bcp.12728. Epub 2015 Sep 15. No abstract available.

21.

Proteinuria as a Noninvasive Marker for Renal Allograft Histology and Failure: An Observational Cohort Study.

Naesens M, Lerut E, Emonds MP, Herelixka A, Evenepoel P, Claes K, Bammens B, Sprangers B, Meijers B, Jochmans I, Monbaliu D, Pirenne J, Kuypers DR.

J Am Soc Nephrol. 2016 Jan;27(1):281-92. doi: 10.1681/ASN.2015010062. Epub 2015 Jul 7.

22.

Progressive decline in tacrolimus clearance after renal transplantation is partially explained by decreasing CYP3A4 activity and increasing haematocrit.

de Jonge H, Vanhove T, de Loor H, Verbeke K, Kuypers DR.

Br J Clin Pharmacol. 2015 Sep;80(3):548-59. doi: 10.1111/bcp.12703. Epub 2015 Aug 3.

23.

Charcot neuroarthropathy after simultaneous pancreas-kidney transplantation: risk factors, prevalence, and outcome.

García Barrado F, Kuypers DR, Matricali GA.

Clin Transplant. 2015 Aug;29(8):712-9. doi: 10.1111/ctr.12572. Epub 2015 Jul 14.

PMID:
26033225
24.

FK506 reduces neuroinflammation and dopaminergic neurodegeneration in an α-synuclein-based rat model for Parkinson's disease.

Van der Perren A, Macchi F, Toelen J, Carlon MS, Maris M, de Loor H, Kuypers DR, Gijsbers R, Van den Haute C, Debyser Z, Baekelandt V.

Neurobiol Aging. 2015 Mar;36(3):1559-68. doi: 10.1016/j.neurobiolaging.2015.01.014. Epub 2015 Jan 21.

PMID:
25660193
25.

Combined effects of CYP3A5*1, POR*28, and CYP3A4*22 single nucleotide polymorphisms on early concentration-controlled tacrolimus exposure in de-novo renal recipients.

Kuypers DR, de Loor H, Naesens M, Coopmans T, de Jonge H.

Pharmacogenet Genomics. 2014 Dec;24(12):597-606. doi: 10.1097/FPC.0000000000000095.

PMID:
25322286
26.

The CYP3A4*22 C>T single nucleotide polymorphism is associated with reduced midazolam and tacrolimus clearance in stable renal allograft recipients.

de Jonge H, Elens L, de Loor H, van Schaik RH, Kuypers DR.

Pharmacogenomics J. 2015 Apr;15(2):144-52. doi: 10.1038/tpj.2014.49. Epub 2014 Oct 7.

PMID:
25287072
27.

The histology of kidney transplant failure: a long-term follow-up study.

Naesens M, Kuypers DR, De Vusser K, Evenepoel P, Claes K, Bammens B, Meijers B, Sprangers B, Pirenne J, Monbaliu D, Jochmans I, Lerut E.

Transplantation. 2014 Aug 27;98(4):427-35. doi: 10.1097/TP.0000000000000183.

PMID:
25243513
28.

Alemtuzumab induction therapy in kidney transplantation.

Kuypers DR.

Lancet. 2014 Nov 8;384(9955):1649-51. doi: 10.1016/S0140-6736(14)61174-0. Epub 2014 Jul 28. No abstract available.

PMID:
25078307
29.

Time course of asymmetric dimethylarginine and symmetric dimethylarginine levels after successful renal transplantation.

Claes KJ, Bammens B, Kuypers DR, Meijers B, Naesens M, Sprangers B, Vanrenterghem Y, Lerut E, de Loor H, Evenepoel P.

Nephrol Dial Transplant. 2014 Oct;29(10):1965-72. doi: 10.1093/ndt/gfu219. Epub 2014 Jun 23.

PMID:
24957811
30.

Genetic polymorphisms in IL-2, IL-10, TGF-β1, and IL-2RB and acute rejection in renal transplant patients.

Chen Z, Bouamar R, Van Schaik RH, De Fijter JW, Hartmann A, Zeier M, Budde K, Kuypers DR, Weimar W, Hesselink DA, Van Gelder T.

Clin Transplant. 2014 Jun;28(6):649-55. doi: 10.1111/ctr.12346. Epub 2014 Jun 3.

PMID:
24579958
31.

Pharmacokinetic modeling of enterohepatic circulation of mycophenolic acid in renal transplant recipients.

Colom H, Lloberas N, Andreu F, Caldés A, Torras J, Oppenheimer F, Sanchez-Plumed J, Gentil MA, Kuypers DR, Brunet M, Ekberg H, Grinyó JM.

Kidney Int. 2014 Jun;85(6):1434-43. doi: 10.1038/ki.2013.517. Epub 2014 Jan 8.

32.

Impact of POR*28 on the pharmacokinetics of tacrolimus and cyclosporine A in renal transplant patients.

Elens L, Hesselink DA, Bouamar R, Budde K, de Fijter JW, De Meyer M, Mourad M, Kuypers DR, Haufroid V, van Gelder T, van Schaik RH.

Ther Drug Monit. 2014 Feb;36(1):71-9. doi: 10.1097/FTD.0b013e31829da6dd.

PMID:
24061445
33.

Impact of CYP3A5 genotype on tacrolimus versus midazolam clearance in renal transplant recipients: new insights in CYP3A5-mediated drug metabolism.

de Jonge H, de Loor H, Verbeke K, Vanrenterghem Y, Kuypers DR.

Pharmacogenomics. 2013 Sep;14(12):1467-80. doi: 10.2217/pgs.13.133.

PMID:
24024898
34.

Chronic wounds in a kidney transplant recipient with moderate renal impairment.

Vanparys J, Sprangers B, Sagaert X, Kuypers DR.

Acta Clin Belg. 2013 Mar-Apr;68(2):128-31.

PMID:
23967723
35.

Recurrence of glomerulonephritis after renal transplantation.

Sprangers B, Kuypers DR.

Transplant Rev (Orlando). 2013 Oct;27(4):126-34. doi: 10.1016/j.trre.2013.07.004. Epub 2013 Aug 15. Review.

PMID:
23954034
36.

Aortic calcifications and arterial stiffness as predictors of cardiovascular events in incident renal transplant recipients.

Claes KJ, Heye S, Bammens B, Kuypers DR, Meijers B, Naesens M, Vanrenterghem Y, Evenepoel P.

Transpl Int. 2013 Oct;26(10):973-81. doi: 10.1111/tri.12151. Epub 2013 Jul 19.

37.

Urinary connective tissue growth factor is associated with human renal allograft fibrogenesis.

Metalidis C, van Vuuren SH, Broekhuizen R, Lerut E, Naesens M, Bakker SJ, Wetzels JF, Goldschmeding R, Kuypers DR.

Transplantation. 2013 Sep 15;96(5):494-500. doi: 10.1097/TP.0b013e31829b07e1.

PMID:
23803600
38.

Efficacy of sotrastaurin plus tacrolimus after de novo kidney transplantation: randomized, phase II trial results.

Russ GR, Tedesco-Silva H, Kuypers DR, Cohney S, Langer RM, Witzke O, Eris J, Sommerer C, von Zur-Mühlen B, Woodle ES, Gill J, Ng J, Klupp J, Chodoff L, Budde K.

Am J Transplant. 2013 Jul;13(7):1746-56. doi: 10.1111/ajt.12251. Epub 2013 May 13.

39.

Response to "CYP3A5 genotype, but not CYP3A4*1b, CYP3A4*22, or hematocrit, predicts tacrolimus dose requirements in Brazilian renal transplant patients".

de Jonge H, Kuypers DR.

Clin Pharmacol Ther. 2013 Aug;94(2):202-3. doi: 10.1038/clpt.2013.94. Epub 2013 May 9. No abstract available.

PMID:
23665867
40.

Response to "pretransplantation pharmacokinetic assessments to predict posttransplantation dosing requirements in renal transplant recipients: what is known?".

de Jonge H, Kuypers DR.

Clin Pharmacol Ther. 2013 Apr;93(4):307-8. doi: 10.1038/clpt.2012.234. Epub 2012 Dec 6. No abstract available.

PMID:
23340478
41.

Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring.

Kuypers DR, Peeters PC, Sennesael JJ, Kianda MN, Vrijens B, Kristanto P, Dobbels F, Vanrenterghem Y, Kanaan N; ADMIRAD Study Team.

Transplantation. 2013 Jan 27;95(2):333-40. doi: 10.1097/TP.0b013e3182725532.

PMID:
23263559
42.

Pharmacogenetics in solid organ transplantation: a transition from kinetics to dynamics.

Kuypers DR.

Pharmacogenomics. 2012 Nov;13(15):1679-83. doi: 10.2217/pgs.12.155. No abstract available.

43.

Chronic histological damage in early indication biopsies is an independent risk factor for late renal allograft failure.

Naesens M, Kuypers DR, De Vusser K, Vanrenterghem Y, Evenepoel P, Claes K, Bammens B, Meijers B, Lerut E.

Am J Transplant. 2013 Jan;13(1):86-99. doi: 10.1111/j.1600-6143.2012.04304.x. Epub 2012 Nov 8.

44.

In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients.

de Jonge H, de Loor H, Verbeke K, Vanrenterghem Y, Kuypers DR.

Clin Pharmacol Ther. 2012 Sep;92(3):366-75. doi: 10.1038/clpt.2012.109. Epub 2012 Aug 8.

PMID:
22871995
45.

Occupational radiation dose: percutaneous interventional procedures on hemodialysis arteriovenous fistulas and grafts.

Heye S, Maleux G, Oyen RH, Claes K, Kuypers DR.

Radiology. 2012 Jul;264(1):278-84. doi: 10.1148/radiol.12110978. Epub 2012 May 1.

PMID:
22550308
46.

Management of polyomavirus-associated nephropathy in renal transplant recipients.

Kuypers DR.

Nat Rev Nephrol. 2012 Apr 17;8(7):390-402. doi: 10.1038/nrneph.2012.64. Review.

PMID:
22508181
47.

Conversion to tacrolimus once-daily from ciclosporin in stable kidney transplant recipients: a multicenter study.

Rostaing L, Sánchez-Fructuoso A, Franco A, Glyda M, Kuypers DR, Jaray J.

Transpl Int. 2012 Apr;25(4):391-400. doi: 10.1111/j.1432-2277.2011.01409.x. Epub 2011 Dec 27.

48.

Impact of vascular calcification on corrected QT interval at the time of renal transplantation.

Claes KJ, Heye S, Nuyens D, Bammens B, Kuypers DR, Vanrenterghem Y, Evenepoel P.

Am J Nephrol. 2012;35(1):24-30. doi: 10.1159/000334597. Epub 2011 Dec 6.

PMID:
22143191
49.

Diagnosis and prevention of chronic kidney allograft loss.

Nankivell BJ, Kuypers DR.

Lancet. 2011 Oct 15;378(9800):1428-37. doi: 10.1016/S0140-6736(11)60699-5. Review.

PMID:
22000139
50.

Mycophenolic acid-related diarrhea is not associated with polymorphisms in SLCO1B nor with ABCB1 in renal transplant recipients.

Bouamar R, Hesselink DA, van Schaik RH, Weimar W, van der Heiden IP, de Fijter JW, Kuypers DR, van Gelder T.

Pharmacogenet Genomics. 2012 Jun;22(6):399-407. doi: 10.1097/FPC.0b013e32834a8650.

PMID:
21878834

Supplemental Content

Loading ...
Support Center